Potensi terapi gen berbasis Small Interference RNA (SIRNA) terhadap infeksi SARS-CoV-2
Abstract
Saat ini, dunia sedang menghadapi krisis kesehatan global. Coronavirus Disease 2019 (COVID-19) masih menjadi penyebab penderitaan banyak orang. Sampai saat ini, ada banyak obat COVID-19 yang sedang diuji, tetapi tidak ada terapi yang terverifikasi bisa menargetkan virus secara khusus. Pengobatan berbasis small interference RNA (siRNA) dapat memberikan solusi yang efektif dalam memerangi COVID-19. siRNA adalah sekuens RNA bersama-sama dengan RNA-Induced Silencing System (RISC), mengikat molekul target mRNA sehingga dapat menghambat translasi dan ekspresinya. Penggunaan Lipid nanoparticle (LNP) sebagai pembawa siRNA untuk pengiriman muatan terapeutik menawarkan keuntungan dengan mengurangi degradasi enzimatik dan sekuestrasi oleh sistem retikuloendotel. Namun, represi siRNA pada SARS-CoV-2 bersifat sementara, dan efek dari penekanan virus hilang setelah 48 jam, menunjukkan bahwa formulasi LNP-siRNA sebagai agen terapeutik, kemungkinan besar akan memerlukan rejimen intravena setiap hari selama infeksi virus puncak sehingga untuk optimalisasi lebih lanjut modifiaksi perlu dilakukan.
Kata Kunci: COVID-19, nanoparticle, LNP, SARS-CoV-2, and siRNA
Keywords
References
United Nations. Health - United Nations Sustainable Development [Internet]. United Nations Sustainable Development. 2018. Available from: https://www.un.org/sustainabledevelopment/health/
World Health Organization. WHO COVID-19 dashboard [Internet]. covid19.who.int. 2021. Available from: https://covid19.who.int/
World Health Organization. Novel Coronavirus [Internet]. www.who.int. 2021. Available from: https://www.who.int/indonesia/news/novel-coronavirus
Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol [Internet]. 2020;41(12):1100–15. Available from: https://doi.org/10.1016/j.it.2020.10.004
Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281–6.
Ouassou H, Kharchoufa L, Bouhrim M, Daoudi NE, Imtara H, Bencheikh N, et al. The Pathogenesis of Coronavirus Disease 2019 (COVID-19): Evaluation and Prevention. J Immunol Res. 2020;2020.
Ghosh S, Mohammad Firdous S, Nath A, Professor A. Letter to the editor: siRNA COULD BE A POTENTIAL THERAPY FOR COVID-19. EXCLI J [Internet]. 2020;19:528–31. Available from:http://dx.doi.org/10.17179/excli2020-1328
Idris A, Davis A, Supramaniam A, Acharya D, Kelly G, Tayyar Y, et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther [Internet].2021;29(7):2219–26. Available from: https://doi.org/10.1016/j.ymthe.2021.05.004
Medeiros IG, Khayat AS, Stransky B, Santos S, Assumpção P, Estefano J, et al. A small interfering RNA (siRNA) database for SARS-CoV-2. Sci Reports | [Internet]. 123AD;11:8849. Available from: https://doi.org/10.1038/s41598-021-88310-8
Nikam, R. R., & Gore KR. Journey of siRNA: Clinical Developments and Targeted Delivery. Nucleic Acid Ther [Internet]. 2018;28(4):209–24. Available from: https://doi.org/10.1089/nat.2017.0715
Rinaldi A. RNA to the rescue . EMBO Rep. 2020;21(7):1–6.
Mehta A, Michler T, Merkel OM. PROGRESS REPORT www.advhealthmat.de siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies? 2021; Available from: https://doi.org/10.1002/adhm.202001650
Niktab I, Haghparast M, Beigi M-H, Megraw TL, Kiani A GK. Design of advanced siRNA therapeutics for the treatment of COVID-19. Meta Gene [Internet]. 2021; Available from: https://pubmed.ncbi.nlm.nih.gov/33996501/
Sajid MI, Moazzam M, Cho Y, Kato S, Xu A, Way JJ et al. siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses. Mol Pharm [Internet]. 2021;18(6):2105–21. Available from: https://doi.org/10.1021/acs.molpharmaceut.0c01239
Uludağ H, Parent K, Aliabadi HM, Haddadi A. Prospects for RNAi Therapy of COVID-19. Front Bioeng Biotechnol. 2020;8(July):1–15.
Yang N, Shen H-M. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19. Int J Biol Sci [Internet]. 2020;2020(10):1724–31. Available from: http://www.ijbs.com//creativecommons.org/licenses/by/4.0/
Ullah A, Qazi J, Rahman L, Kanaras AG, Khan WS, Hussain I, et al. Nanoparticles-assisted delivery of antiviral-siRNA as inhalable treatment for human respiratory viruses: A candidate approach against SARS-COV-2. 2020;
Mahfuz Ali Khan Shawan M, Ranjan Sharma A, Bhattacharya M, Mallik B, Akhter F, Salman Shakil M, et al. Designing an effective therapeutic siRNA to silence RdRp gene of SARS-CoV-2 siRNA Post-transcriptional gene silencing SARS-CoV-2 RNA-dependent RNA polymerase. 2021; Available from: https://doi.org/10.1016/j.meegid.2021.104951
Hasan M, Ashik AI, Chowdhury MB, Tasnim AT, Nishat ZS, Hossain T, et al. Computational prediction of potential siRNA and human miRNA sequences to silence orf1ab associated genes for future therapeutics against SARS-CoV-2. Informatics Med Unlocked [Internet]. 2021;24:100569. Available from: https://doi.org/10.1016/j.imu.2021.100569
Dana H, Chalbatani GM, Mahmoodzadeh H, Karimloo R, Rezaiean O, Moradzadeh A, et al. Molecular Mechanisms and Biological Functions of siRNA. Int J Biomed Sci [Internet]. 2017;13(2):48–57. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542916/
Robert K, Arkadiusz D. Molecular and Serological Tests for COVID-19 . A Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics. Diagnostics. 2020;10(6)
DOI: 10.24815/jks.v22i4.23202
Refbacks
- There are currently no refbacks.